FAS and metastatic neoplasm: However, patients with metastatic disease had a higher percentage of PD-1+ CD8+ T cells and Fas+ CD8 T cells than patients with nonmetastatic disease (51.86% (25.15% and 84.58% vs. 71.74% respectively p < 0.05) (Figure 3).